SCHEMBL392669

SCHEMBL392669

C1=NNSc2cccnc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL518987 0.69 ALDH1A1 (0.30)
SCHEMBL27693760 0.67 TRPA1 (0.39)
Ammonia Solution, Strong SCHEMBL28016359 0.65 TRPA1 (0.38)
SCHEMBL8371992 0.65
SCHEMBL6207702 0.64
SCHEMBL1913184 0.64
SCHEMBL9940454 0.64
SCHEMBL6208056 0.63 TRPA1 (0.58)
SCHEMBL31408049 0.62 MEN1 (0.32)
SCHEMBL14989970 0.61 AXL (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254871-A1 Compounds for the Treatment of Inflammation of the Central Nervous System NEUROTEC PHARMA, S.L. (ES) 2007-11-01 US claimed
EP-1782812-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATION OF THE CENTRAL NERVOUS SYSTEM Neurotec Pharma, S.L. (ES) 2007-05-09 EP claimed
EP-3545958-B1 SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF ESSENTIALIS INC (US) 2024-07-10 EP disclosed
CN-107056731-B benzothiadiazinone derivative, preparation method and application thereof 深圳海王医药科技研究院有限公司 2019-12-10 CN disclosed
US-8415344-B2 Method of treating depression BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2013-04-09 US disclosed
US-20120129826-A1 Method of Treating Depression BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2012-05-24 US disclosed
US-8101600-B2 Method of treating depression BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2012-01-24 US disclosed
US-20100160300-A1 Method of Treating Depression BROOKHAVEN SCIENCE ASSOCIATES, LLC (US) 2010-06-24 US disclosed
EP-1663239-A4 POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER CEDARS SINAI MEDICAL CENTER (US) 2008-07-23 EP disclosed
US-20070254871-A1 Compounds for the Treatment of Inflammation of the Central Nervous System NEUROTEC PHARMA, S.L. (ES) 2007-11-01 US disclosed
US-20070254871-A1 Compounds for the Treatment of Inflammation of the Central Nervous System NEUROTEC PHARMA, S.L. (ES) 2007-11-01 US disclosed
US-5792764-A ENDOCRINE DISORDERS ESPECIALLY AS A K(ATP)-CHANNEL MODULATOR NOVO NORDISK A/S (DK) 1998-08-11 US disclosed
WO-1997026265-A1 FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO disclosed
WO-1997026264-A1 PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1997-07-24 WO disclosed
US-5459138-A Dysfunctions of glutamatergic neurotransmission associated with learning and memory ADIR ET COMPAGNIE (FR) 1995-10-17 US disclosed
US-5459138-A Dysfunctions of glutamatergic neurotransmission associated with learning and memory ADIR ET COMPAGNIE (FR) 1995-10-17 US disclosed
EP-0618209-A1 Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1994-10-05 EP disclosed
EP-0618209-A1 Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1994-10-05 EP disclosed
WO-1994020460-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1994-09-15 WO disclosed
US-4025510-A DYES FOR POLYESTERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-05-24 US disclosed